Carmignac Gestion Clearside Biomedical, Inc. Transaction History
Carmignac Gestion
- $6.4 Billion
- Q3 2025
A detailed history of Carmignac Gestion transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Carmignac Gestion holds 100,556 shares of CLSD stock, worth $397,196. This represents 0.01% of its overall portfolio holdings.
Number of Shares
100,556
Previous 1,508,342
93.33%
Holding current value
$397,196
Previous $1.21 Million
67.16%
% of portfolio
0.01%
Previous 0.02%
Shares
13 transactions
Others Institutions Holding CLSD
# of Institutions
19Shares Held
3.99MCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA2.2MShares$8.68 Million3.43% of portfolio
-
Black Rock Inc. New York, NY798KShares$3.15 Million0.0% of portfolio
-
Northeast Financial Consultants Inc Westport, CT93KShares$367,3500.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC87KShares$343,6500.0% of portfolio
-
Credit Suisse Ag Zurich, V825KShares$98,7500.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $238M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...